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Abstract
Alpha1-antitrypsin (AAT) is a highly polymorphic protein with more than 120 variants that are classified as normal
(normal protein secretion), deficient (reduced circulating AAT level caused by defective secretion) or null (no protein
secretion). Alpha1-antitrypsin deficiency, one of the most common genetic disorders, predisposes adults to pulmo-
nary emphysema and, to a lesser extent, chronic liver disease and cirrhosis. In this report, we provide additional se-
quence data for alpha1-antitrypsin based on the characterization of a novel variant detected in a 53-year-old
heterozygous patient with chronic obstructive pulmonary disease. The mutation occurred on a PI*M2 base allele and
was characterized by a T  C transition at nt 97 in exon II that led to the replacement of phenylalanine by leucine
(F33L). Since the mutation was found in the heterozygous state with the expression of a normally secreted variant
(PI*M1) it was not possible to assess the pattern of F33L secretion. However, computational analyses based on evo-
lutionary,structuralandfunctionalinformationindicatedareductionof23Å
3inthesidechainvolumeandthecreation
of a cavity in the protein hydrophobic core that likely disturbed the tridimensional structure and folding of AAT. The
accuracy of the in silico prediction was confirmed by testing known mutations.
Key words: alpha1-antitrypsin, computational analysis, damaging mutation.
Received: February 19, 2010; Accepted: June 2, 2010.
Alpha1-antitrypsin(AAT)isthearchetypalproteinof
the serine proteinase inhibitor (SERPIN) superfamily.
AAT is synthesized in hepatocytes and macrophages and
protects the lower respiratory tract from proteolytic degra-
dation by neutrophil elastase (Perlino et al., 1987). This
protein is encoded by a highly polymorphic locus, PI (for
ProteinaseInhibitor),thatconsistsofsevenexonsdispersed
over 12.2 kb on chromosome 14q31-32.3 (Li et al., 1998).
The two parental PI genes are codominantly expressed and
dictate the AAT serum level (Brantly et al., 1991). The
most common PI allele is designated PI*M and has a gene
frequencyof0.95.HomozygosityofthePI*Malleleresults
in AAT plasma concentrations ranging from 150 to
350 mg/dL, which provides a sufficient protease/antipro-
tease balance to protect lung tissues. The most frequent de-
ficient variants are PI*S (p.E264V) and PI*Z (p.E342L).
PI*S produces approximately 60% of PI*M alpha1-anti-
trypsin and the PI*Z allele produces 10%-15% of normal
AAT levels. Other rarer deficiency states arising from null
alleles result in no detectable AAT protein (Crystal, 1990).
The major clinical consequence of AAT deficiency
(AATD) is a high risk of early onset panlobular emphy-
sema and, to a lesser extent, chronic liver disease and cir-
rhosis (Mahadeva and Lomas, 1998). Current gene
frequency data indicate that AATD is one of the most com-
moninheriteddisordersworldwide(deSerresetal.,2007).
Inthisreport,weprovideadditionalsequencedatafor
AAT based on the characterization of a novel AAT muta-
tion discovered in a Tunisian patient with chronic obstruc-
tive pulmonary disease (COPD).
A 53-year-old man diagnosed with pulmonary em-
physema was enrolled in a targeted AATD screening pro-
gram run by the Pneumology Department of Ibn Eljazzar
Hospital in Kairouan (central Tunisia). Based on a previ-
ously described algorithm (Denden et al., 2009), all pa-
tients with obstructive lung disease and an AAT level
< 150 mg/dL (threshold value) attended at this unit are
screened for AATD. In this case, the AAT plasma concen-
tration was 132 mg/dL, as measured using an immune
turbidimetric assay (Denden et al., 2009). The patient, an
ex-smoker with a history of 28 pack-years, presented the
common symptoms of airway obstructive disease, i.e.,
breathlessness, cough, wheeze and phlegm. These symp-
toms began at 50 years of age. During a two-year fol-
low-up, the patient showed increasing dyspnea and weight
loss. An intradermal skin test and the quantification of total
IgE (22.5 IU/mL) indicated that there was no atopy. At his
first presentation, chest radiographs showed hyperinflation
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Short Communicationwith an anterior diaphragmatic angle of 107 degrees in lat-
eral view and a retrosternal airspace of 5.2 cm. Decreased
lungmarkingsandbullaewerelocalizedinthelowerzones.
Chestcomputedaxialtomographyconfirmedtheemphyse-
matous state of the lower lobe and the presence of pulmo-
nary parenchymal destruction seen as large areas of hypo-
lucency and the presence of bullae. Baseline lung function
tests were consistent with the onset of severe COPD: the
forcedexpiratoryvolumein1s(FEV1)was28%ofthepre-
dicted value and the FEV1/FVC (forced vital capacity) ra-
tiowas70%.Afterbronchodilatorinhalation,theFEV1im-
proved 4.8% relative to the baseline value. During the
follow-up, lung function impairment, assigned by the an-
nual decline in FEV1 (FEV1), was 213 mL/year.
Blood samples were collected for analysis after ob-
taining the patients informed consent and the investigation
wasapprovedbythelocalEthicsCommitteesoftheinstitu-
tions involved. DNA was isolated from whole peripheral
blood using a standard phenol-chloroform method. Geno-
typingbyRFLP-PCRwasusedtodetectthemostprevalent
AATD mutations (S and Z) (Denden et al., 2009). This
analysis does not report any S or Z AAT allele. Sequencing
of the AAT gene coding regions as previously described
(Denden et al., 2009) revealed a novel point mutation at
c.97 T  C (Figure 1). This substitution led to the replace-
ment of phenylalanine by leucine (F33L). Since the muta-
tion was found in the heterozygous state, the PCR product
ofexonIIoftheSERPINA1genewasclonedtoidentifythe
allele with the mutated base. Cloning was done using a
TOPO-TA cloning kit (Invitrogen Corporation, Carlsbad,
CA).Thesequencingofpositiveclonesconfirmedthepres-
ence of the c.97 T  C point mutation on the PI*M2
(c.302 G  A) allele (Figure 2).
Although the mutation occurred in the heterozygous
state, mild AATD, usually observed in subjects carrying
only one deficient allele, could explain the disease. Indeed,
a meta-analysis of previous studies indicated an increase in
the risk of COPD in PI*MZ heterozygotes (Hersh et al.,
2004). The serum AAT level in this patient (132 mg/dL)
was within the normal AAT range of the Tunisian popula-
tion [120-280 mg/dL] (Denden et al., 2008). However, the
patient’s heterozygous state meant that the expression of a
normal allele (PI*M1) could have masked any deficiency
arising from the mutated allele. Additional investigations
were needed to elucidate this deficiency but, unfortunately,
none of the patient’s family members was available for fur-
ther study.
To circumvent this limitation, computational meth-
ods were used to assess whether the mutation was detri-
mental to the protein structure and/or function. Changes in
thestabilityofthemutantproteincomparedtothewildtype
protein were predicted using the Auto-Mute server (Masso
and Vaisman, 2008). SIFT (Sorting Intolerant from Toler-
ant) software (Ng and Henikoff, 2002) was used to predict
tolerance to the causal non-synonymous SNP (nsSNP) on
the basis of sequence conservation in the protein family.
The PolyPhen bioinformatic algorithm (Ramensky et al.,
2002) was used to predict the influence of the mutation
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Figure 1 - Partial exon II sequence of the SERPINA1 gene (genomic DNA) reveals a novel c.97 T  C mutation at the heterozygous state.
Figure 2 - Partial exon II sequence of the SERPINA1 gene (cloned DNA) reveals the presence of c.97 T  C and c.302 G  A substitutions on the same
chromosome.based on data derived from structural parameters, func-
tional annotations and evolutionary information, and the
HybridMeth algorithm (Capriotti et al., 2006) was used to
predicttheeffectofthensSNPbasedonevolutionaryinfor-
mation. The p.F33L mutant was predicted to be 1.41 kcal
mol
-1 less stable than the wild type protein (PDB ID: 1atu).
SIFTsoftwareshowedthatthephenylalanineatposition33
was highly conserved in the protein family (score of 0.00),
while the HybridMeth algorithm favored a disease-asso-
ciated nsSNP with a reliability index of 7. PolyPhen pre-
dicted that the p.F33L mutation was possibly deleterious to
AAT (PSIC score difference of 1.882). The PolyPhen deci-
siontreeindicatedthatsubstitutionoftheburiedaminoacid
F by L at position 33 in the AAT-A--helix led to a reduc-
tioninsidechainvolumeof23Å
3andthecreationofacav-
ity. Cavities in the protein hydrophobic core are very likely
to disturb the tridimensional structure and folding of AAT.
In silico analysis with known mutations was used to assess
theaccuracyofthepredictionsandconfirmedthatthecom-
putational analyses based on evolutionary, structural and
functional information were in agreement with previous
findings in vivo and in vitro (Table 1). A neutral effect was
predicted for mutations associated with a normal AAT
level: the common AAT mutations PI*M2 (R101H) and
PI*M3 (E376D) apparently had no effect on the protein
(Table 1). Mutations associated with a low AAT level were
predicted to be damaging: AATD, observed in the most
prevalent deficiency variants PI*S (E264V) and PI*Z
(E342L), was attributed to a change in hydrophobicity and
charge at buried sites of the protein. The rare allele
PI*Mwurzburg (E369S) showed the same abnormality as the
F33L mutation, i.e.,a2 3Å
3 reduction in side chain volume
(Table 1).
In conclusion, we have described a novel rare PI mu-
tation that is likely to be clinically important, as suggested
by computational analyses. Further studies are required to
confirm this finding.
A novel deleterious AAT mutation 635
Table 1 - Computational analysis of alpha1-antitrypsin variants.
Mutation Location Auto-mute SIFT HybridMeth PolyPhen
G expected Tolerance (score) SPBP (RI) PSIC dif-
ference
Substitution
prediction
Substitution effect
Normally secreted variants
R101H hD -0.29 Yes (0.47) Neutral (6) 1.162 benign NA
E376D s4B -0.17 Yes (0.56) Neutral (7) 0.264 benign Hydrophobicity change at buried site of 0.78;
accN: 0.00
A34T hA -2.17 Yes (0.06) Neutral (4) 0.657 benign Distance to MET 385 of 3.345 Å
P88T hD -1.32 Yes (0.59) Neutral (2) 0.937 benign NA
A60T hB-hC -1.35 No (0.02) Neutral (7) 1.001 benign NA
G148R s1A -1.14 Yes (0.64) Neutral (3) 0.631 benign Charge change at exposed site, accN: 0.83
E204K s4C -0.89 Yes (0.98) Neutral (3) 0.134 benign NA
L276P hH -2.22 Yes (0.27) Disease (5) 0.931 benign Distance to ILE 375B of 3.807 Å
P362T s1C -1.45 Yes (0.52) Neutral (8) 1.411 benign NA
AAT Deficient variants
E342L s5A 0.87 No (0.00) Disease (7) 3.190 probably
damaging
Hydrophobicity change at buried site of
1.59, accN: 0.03; charge change at buried site
E264V hG 0.32 No (0.03) Disease (4) 1.773 probably
damaging
Hydrophobicity change at buried site of 1.48;
LYS 383H distance 2.658 Å; charge change at
buried site, accN: 0.03
R223C thIs5A -1.18 No (0.04) Disease (3) 0.671 possibly
damaging
Cavity creation at buried site of -65 Å
3; ligand:
CIT distance 3.818 Å; hydrophobicity change
at buried site of 1.66; charge change at buried
site, accN: 0.15
L41P hA -1.67 No (0.00) Disease (8) 2.621 probably
damaging
Hydrophobicity change at buried site of
1.07, accN: 0.05
K335E s5A -0.17 No (0.00) Disease (5) 1.612 possibly
damaging
Distance to PHE 384B of 5.913 Å
M221T s4C-s2B -2.33 No (0.00) Disease (6) 3.746 probably
damaging
Hydrophobicity change at buried site of
1.02, accN: 0.00
T85M hC-hD 0.07 Yes (0.09) Disease (4) 2.400 probably
damaging
Overpacking of 47 Å
3, accN:0.90
R39C hA -0.86 No (0.00) Disease (7) 2.872 probably
damaging
Cavity creation at buried site of -65 Å
3, accN:
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Mutation Location Auto-mute SIFT HybridMeth PolyPhen
G expected Tolerance (score) SPBP (RI) PSIC dif-
ference
Substitution
prediction
Substitution effect
P369S s4B -1.61 No (0.00) Disease (3) 1.726 possibly
damaging
Cavity creation at buried site of -23 Å
3, accN:
0.20
P369L s4B -1.65 No (0.00) Disease (5) 3.230 probably
damaging
Overpacking of 55 Å
3, accN: 0.20
D256V ts2Bs3B-
hG
0.53 Yes (0.11) Disease (5) 1.698 possibly
damaging
Distance to functional site SER 232A of 5.173
Å; distance to LYS 368B of 3. 307Å
G67E hB-hC -1.02 No (0.00) Disease (8) 2.760 probably
damaging
Overpacking at buried site of 78 Å
3;
hydrophobicity change at buried site of 2.44;
Charge change at buried site, accN: 0.00
A336T s5A -0.26 Yes (0.08) Disease (2) 0.993 probably
damaging
Hydrophobicity change at buried site of 1.08;
distance to PHE 384B of 4.320 Å, accN: 0.00
G225R s4C-s2B -0.48 Yes (0.11) Disease (2) 0.714 probably
damaging
Overpacking at buried site of 133 Å
3; PRO
361B distance 5.919Å; hydrophobicity change
at buried site of 3.3; charge change of a buried
site, accN: 0.00
F33L hA -1.41 No (0.00) Disease (7) 1.882 possibly
damaging
Cavity creation at buried site of -23 Å
3, accN:
0.00
G expected: free energy change of protein stability at 25 °C, pH 7 (kcal mol
-1) computed using the Auto-Mute server; Tolerance: tolerance to substitu-
tion scored using SIFT software; SPBP: sequence and profile based prediction of HybridMeth; RI: reliability index. PSIC difference: Position-Specific
Independent Counts score difference between the two amino acids determined using the PolyPhen tool; accN: normed accessible surface area.
Table 1 (cont.)